Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Stocrin
Active Ingredient: Efavirenz 100mg
Dosage Form: Capsule
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 11 November 2005.
Product: Stocrin
Active Ingredient: Efavirenz 200mg
Dosage Form: Capsule
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 11 November 2005.
Product: Stocrin
Active Ingredient: Efavirenz 50mg
Dosage Form: Capsule
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 11 November 2005.
Product: Stocrin
Active Ingredient: Efavirenz 300mg
Dosage Form: Film-coated tablet
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 25 October 2005.
Product: Stocrin
Active Ingredient: Efavirenz 600mg
Dosage Form: Film-coated tablet
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 25 October 2005.
Dated this 10th day of March 2005.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).